Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 1
2004 2
2005 3
2006 3
2007 6
2008 1
2009 7
2010 6
2011 13
2012 12
2013 10
2014 12
2015 4
2016 12
2017 10
2018 11
2019 14
2020 21
2021 13
2022 23
2023 4
Text availability
Article attribute
Article type
Publication date

Search Results

158 results
Results by year
Filters applied: . Clear all
Page 1
Performance evaluation of automated white matter hyperintensity segmentation algorithms in a multicenter cohort on cognitive impairment and dementia.
Gaubert M, Dell'Orco A, Lange C, Garnier-Crussard A, Zimmermann I, Dyrba M, Duering M, Ziegler G, Peters O, Preis L, Priller J, Spruth EJ, Schneider A, Fliessbach K, Wiltfang J, Schott BH, Maier F, Glanz W, Buerger K, Janowitz D, Perneczky R, Rauchmann BS, Teipel S, Kilimann I, Laske C, Munk MH, Spottke A, Roy N, Dobisch L, Ewers M, Dechent P, Haynes JD, Scheffler K, Düzel E, Jessen F, Wirth M; DELCODE study group. Gaubert M, et al. Among authors: ewers m. Front Psychiatry. 2023 Jan 12;13:1010273. doi: 10.3389/fpsyt.2022.1010273. eCollection 2022. Front Psychiatry. 2023. PMID: 36713907 Free PMC article.
BACKGROUND: White matter hyperintensities (WMH), a biomarker of small vessel disease, are often found in Alzheimer's disease (AD) and their advanced detection and quantification can be beneficial for research and clinical applications. ...After retraining on a DELCODE subs …
BACKGROUND: White matter hyperintensities (WMH), a biomarker of small vessel disease, are often found in Alzheimer's disease (AD) and …
Linking early-life bilingualism and cognitive advantage in older adulthood.
Ballarini T, Kuhn E, Röske S, Altenstein S, Bartels C, Buchholz F, Buerger K, Dechent P, Dobisch L, Ewers M, Fliessbach K, Freiesleben SD, Frommann I, Gabelin T, Glanz W, Görß D, Haynes JD, Incesoy EI, Janowitz D, Kilimann I, Kleineidam L, Kobeleva X, Laske C, Lohse A, Maier F, Munk MH, Perneczky R, Peters O, Priller J, Rauchmann BS, Roy N, Scheffler K, Schneider A, Schott BH, Spottke A, Spruth EJ, Teipel S, Wiltfang J, Wolfsgruber S, Düzel E, Jessen F, Wagner M; DELCODE study group. Ballarini T, et al. Among authors: ewers m. Neurobiol Aging. 2022 Dec 14;124:18-28. doi: 10.1016/j.neurobiolaging.2022.12.005. Online ahead of print. Neurobiol Aging. 2022. PMID: 36706574
Serum IL-6, sAXL, and YKL-40 as systemic correlates of reduced brain structure and function in Alzheimer's disease: results from the DELCODE study.
Brosseron F, Maass A, Kleineidam L, Ravichandran KA, Kolbe CC, Wolfsgruber S, Santarelli F, Häsler LM, McManus R, Ising C, Röske S, Peters O, Cosma NC, Schneider LS, Wang X, Priller J, Spruth EJ, Altenstein S, Schneider A, Fliessbach K, Wiltfang J, Schott BH, Buerger K, Janowitz D, Dichgans M, Perneczky R, Rauchmann BS, Teipel S, Kilimann I, Görß D, Laske C, Munk MH, Düzel E, Yakupow R, Dobisch L, Metzger CD, Glanz W, Ewers M, Dechent P, Haynes JD, Scheffler K, Roy N, Rostamzadeh A, Spottke A, Ramirez A, Mengel D, Synofzik M, Jucker M, Latz E, Jessen F, Wagner M, Heneka MT; DELCODE study group. Brosseron F, et al. Among authors: ewers m. Alzheimers Res Ther. 2023 Jan 12;15(1):13. doi: 10.1186/s13195-022-01118-0. Alzheimers Res Ther. 2023. PMID: 36631909 Free PMC article.
BACKGROUND: Neuroinflammation constitutes a pathological hallmark of Alzheimer's disease (AD). Still, it remains unresolved if peripheral inflammatory markers can be utilized for research purposes similar to blood-based beta-amyloid and neurodegeneration measures. ...Struc …
BACKGROUND: Neuroinflammation constitutes a pathological hallmark of Alzheimer's disease (AD). Still, it remains unresolved if periph …
sTREM2 is associated with amyloid-related p-tau increases and glucose hypermetabolism in Alzheimer's disease.
Biel D, Suárez-Calvet M, Hager P, Rubinski A, Dewenter A, Steward A, Roemer S, Ewers M, Haass C, Brendel M, Franzmeier N; Alzheimer's Disease Neuroimaging Initiative (ADNI). Biel D, et al. Among authors: ewers m. EMBO Mol Med. 2023 Feb 8;15(2):e16987. doi: 10.15252/emmm.202216987. Epub 2023 Jan 9. EMBO Mol Med. 2023. PMID: 36620941 Free article.
Microglial activation occurs early in Alzheimer's disease (AD) and previous studies reported both detrimental and protective effects of microglia on AD progression. ...
Microglial activation occurs early in Alzheimer's disease (AD) and previous studies reported both detrimental and protective effects …
Polygenic Effect on Tau Pathology Progression in Alzheimer's Disease.
Rubinski A, Frerich S, Malik R, Franzmeier N, Ramirez A, Dichgans M, Ewers M; Alzheimer's Disease Neuroimaging Initiative (ADNI). Rubinski A, et al. Among authors: ewers m. Ann Neurol. 2022 Dec 26. doi: 10.1002/ana.26588. Online ahead of print. Ann Neurol. 2022. PMID: 36571564
OBJECTIVE: Polygenic variation accounts for a substantial portion of the risk of Alzheimer's disease (AD), but its effect on the rate of fibrillar-tau accumulation as a key driver of dementia symptoms is unclear. ...We assessed longitudinal tau-positron emission tomography …
OBJECTIVE: Polygenic variation accounts for a substantial portion of the risk of Alzheimer's disease (AD), but its effect on the rate …
Midlife occupational cognitive requirements protect cognitive function in old age by increasing cognitive reserve.
Kleineidam L, Wolfsgruber S, Weyrauch AS, Zulka LE, Forstmeier S, Roeske S, van den Bussche H, Kaduszkiewicz H, Wiese B, Weyerer S, Werle J, Fuchs A, Pentzek M, Brettschneider C, König HH, Weeg D, Bickel H, Luppa M, Rodriguez FS, Freiesleben SD, Erdogan S, Unterfeld C, Peters O, Spruth EJ, Altenstein S, Lohse A, Priller J, Fliessbach K, Kobeleva X, Schneider A, Bartels C, Schott BH, Wiltfang J, Maier F, Glanz W, Incesoy EI, Butryn M, Düzel E, Buerger K, Janowitz D, Ewers M, Rauchmann BS, Perneczky R, Kilimann I, Görß D, Teipel S, Laske C, Munk MHJ, Spottke A, Roy N, Brosseron F, Heneka MT, Ramirez A, Yakupov R, Scherer M, Maier W, Jessen F, Riedel-Heller SG, Wagner M. Kleineidam L, et al. Among authors: ewers m. Front Psychol. 2022 Dec 8;13:957308. doi: 10.3389/fpsyg.2022.957308. eCollection 2022. Front Psychol. 2022. PMID: 36571008 Free PMC article.
INTRODUCTION: Several lifestyle factors promote protection against Alzheimer's disease (AD) throughout a person's lifespan. Although such protective effects have been described for occupational cognitive requirements (OCR) in midlife, it is currently unknown whether …
INTRODUCTION: Several lifestyle factors promote protection against Alzheimer's disease (AD) throughout a person's lifespan. Al …
Strategic white matter hyperintensity locations for cognitive impairment: A multicenter lesion-symptom mapping study in 3525 memory clinic patients.
Coenen M, Kuijf HJ, Huenges Wajer IMC, Duering M, Wolters FJ, Fletcher EF, Maillard PM; Alzheimer's Disease Neuroimaging Initiative; Barkhof F, Barnes J, Benke T, Boomsma JMF, Chen CPLH, Dal-Bianco P, Dewenter A, Enzinger C, Ewers M, Exalto LG, Franzmeier N, Groeneveld O, Hilal S, Hofer E, Koek DL, Maier AB, McCreary CR, Padilla CS, Papma JM, Paterson RW, Pijnenburg YAL, Rubinski A, Schmidt R, Schott JM, Slattery CF, Smith EE, Steketee RME, Sudre CH, van den Berg E, van der Flier WM, Venketasubramanian N, Vernooij MW, Xin X, DeCarli C, Biessels GJ, Biesbroek JM. Coenen M, et al. Among authors: ewers m. Alzheimers Dement. 2022 Dec 12. doi: 10.1002/alz.12827. Online ahead of print. Alzheimers Dement. 2022. PMID: 36504357
Lifelong experiences as a proxy of cognitive reserve moderate the association between connectivity and cognition in Alzheimer's disease.
Ersoezlue E, Rauchmann BS, Schneider-Axmann T, Wagner M, Ballarini T, Tato M, Utecht J, Kurz C, Papazov B, Guersel S, Burow L, Koller G, Stöcklein S, Keeser D, Bartels C, Brosseron F, Buerger K, Cetindag AC, Dechent P, Dobisch L, Ewers M, Fliessbach K, Frommann I, Haynes JD, Heneka MT, Janowitz D, Kilimann I, Kleinedam L, Laske C, Maier F, Metzger CD, Munk MH, Peters O, Preis L, Priller J, Ramirez A, Roeske S, Roy N, Scheffler K, Schneider A, Spottke A, Spruth EJ, Teipel S, Wiltfang J, Wolfsgruber S, Yakupov R, Duezel E, Jessen F, Perneczky R. Ersoezlue E, et al. Among authors: ewers m. Neurobiol Aging. 2023 Feb;122:33-44. doi: 10.1016/j.neurobiolaging.2022.05.015. Epub 2022 Oct 23. Neurobiol Aging. 2023. PMID: 36476760
Alzheimer's disease (AD) is associated with alterations in functional connectivity (FC) of the brain. ...
Alzheimer's disease (AD) is associated with alterations in functional connectivity (FC) of the brain. ...
Functional network segregation is associated with attenuated tau spreading in Alzheimer's disease.
Steward A, Biel D, Brendel M, Dewenter A, Roemer S, Rubinski A, Luan Y, Dichgans M, Ewers M, Franzmeier N; Alzheimer's Disease Neuroimaging Initiative (ADNI). Steward A, et al. Among authors: ewers m. Alzheimers Dement. 2022 Nov 25. doi: 10.1002/alz.12867. Online ahead of print. Alzheimers Dement. 2022. PMID: 36433865
INTRODUCTION: Lower network segregation is associated with accelerated cognitive decline in Alzheimer's disease (AD), yet it is unclear whether less segregated brain networks facilitate connectivity-mediated tau spreading. ...HIGHLIGHTS: Higher brain network segregation is …
INTRODUCTION: Lower network segregation is associated with accelerated cognitive decline in Alzheimer's disease (AD), yet it is uncle …
Combining tau-PET and fMRI meta-analyses for patient-centered prediction of cognitive decline in Alzheimer's disease.
Biel D, Luan Y, Brendel M, Hager P, Dewenter A, Moscoso A, Otero Svaldi D, Higgins IA, Pontecorvo M, Römer S, Steward A, Rubinski A, Zheng L, Schöll M, Shcherbinin S, Ewers M, Franzmeier N; Alzheimer’s Disease Neuroimaging Initiative. Biel D, et al. Among authors: ewers m. Alzheimers Res Ther. 2022 Nov 7;14(1):166. doi: 10.1186/s13195-022-01105-5. Alzheimers Res Ther. 2022. PMID: 36345046 Free PMC article.
BACKGROUND: Tau-PET is a prognostic marker for cognitive decline in Alzheimer's disease, and the heterogeneity of tau-PET patterns matches cognitive symptom heterogeneity. ...Further, we aimed to determine whether tau-PET-informed personalized cognitive composites capture …
BACKGROUND: Tau-PET is a prognostic marker for cognitive decline in Alzheimer's disease, and the heterogeneity of tau-PET patterns ma …
158 results